Press Release: BERG : BERG to Present Phase 1 Results of BPM 31510-IV and Identifies Therapeutic Opportunities for Recurrent GBM Patients at 2021 American Society of Clinical Oncology (ASCO) Meeting

FRAMINGHAM, Mass., June 2, 2021 /PRNewswire/ -- BERG, a clinical-stage biotech that employs patient biology and artificial intelligence (AI) to research diseases and develop innovative treatments, today announced results from a recently completed Phase 1 study of its investigational drug,...